MNCLCDA: predicting circRNA-drug sensitivity associations by using mixed neighbourhood information and contrastive learning

Guanghui Li, Feifan Zeng, Jiawei Luo, Cheng Liang, Qiu XiaoBMC Medical Informatics Decis. Mak 2023 · OpenReview

TL;DR

This paper introduces MNCLCDA, a novel computational framework designed to predict associations between circular RNAs (circRNAs) and drug sensitivity. By integrating diverse data sources and employing advanced graph-based learning techniques, MNCLCDA aims to accelerate the discovery of potential drug targets and improve treatment efficacy, overcoming the limitations of traditional experimental methods.

What Problem Does This Paper Address?

Identifying how a cell's sensitivity to a drug is influenced by specific molecules, like circRNAs, is crucial for developing effective cancer treatments and overcoming drug resistance. However, experimentally verifying these complex relationships is a slow and costly process. While computational methods have emerged, the known associations between circRNAs and drug sensitivities are still incomplete, necessitating more accurate prediction tools. This paper addresses the need for an efficient and robust computational approach to predict these associations, thereby aiding medical research and clinical trial design.

Methods

MNCLCDA employs a multi-stage approach:

  • Similarity Quantification: It first calculates similarity between circRNAs and drugs using three sources: circRNA gene sequence, drug chemical structure, and Gaussian Interaction Profile (GIP) kernel similarity derived from known associations.
  • Noise Reduction with Random Walk with Restart (RWR): To mitigate noise in the similarity data, RWR is applied to the circRNA and drug similarity networks. This technique helps capture essential features by simulating random walks on the network and identifying important nodes.
  • Mixed-Neighbourhood Graph Convolutional Network (GCN): A novel GCN architecture is used to learn node embeddings. Unlike standard GCNs that focus on immediate neighbors, this "mixed-neighbourhood" approach considers both direct (heterogeneous) and higher-order (homogeneous) neighbors, capturing richer contextual information and reducing oversmoothing.
  • Contrastive Learning: A graph-based contrastive learning task is integrated to enhance the model's robustness and discriminative power. This involves training the model to distinguish between embeddings of the original graph and a corrupted version, thereby improving the quality of learned representations.
  • Double Laplacian-Regularized Least-Squares Prediction: Finally, a double Laplacian-regularized least-squares method is applied to the kernel matrices derived from the learned circRNA and drug embeddings to predict potential associations.

Datasets

The study utilizes the following datasets:

  • circRNA-drug sensitivity association data: Obtained from the circRic database [16], which was originally compiled from the GDSC database [19]. This dataset comprises 80,076 circRNA-drug sensitivity associations, which were filtered to identify significant associations (false discovery rate < 0.05), resulting in a benchmark dataset of 4134 associations involving 271 circRNAs and 218 drugs.
  • Host gene sequence data: Accessed from the NCBI Gene Database [20].
  • Drug structural information: Obtained from the PubChem database [21].
  • CTRP database [50]: Used for validating the novel associations predicted by the model in case studies.

Key Insights and Ideas

  • The power of multi-modal data integration: Combining sequence, structural, and interaction profile data significantly enhances the ability to predict circRNA-drug sensitivity associations.
  • RWR for robust feature extraction: Preprocessing similarity networks with RWR effectively denoises the data and extracts more meaningful features, crucial for downstream prediction.
  • Mixed-neighbourhood GCNs capture richer context: Moving beyond immediate neighbors in GCNs allows for a more comprehensive understanding of node relationships, leading to better embeddings.
  • Contrastive learning boosts model resilience: The integration of contrastive learning makes the model more robust to noise and variations in the data, improving its overall predictive performance.
  • Laplacian regularization for accurate prediction: The double Laplacian-regularized least-squares method provides a stable and effective way to infer associations from learned embeddings.

Key Results

  • Superior performance: MNCLCDA outperformed six other state-of-the-art methods in both five-fold and ten-fold cross-validation experiments. For instance, in 5-CV, MNCLCDA achieved a mean AUC of 0.9084, which was notably higher than other methods, with the closest competitor (GATECDA) achieving 0.8877.
  • High accuracy metrics: The model consistently achieved high scores across various metrics, including AUC, AUPR, accuracy, recall, precision, and F1-score. For example, in 5-CV, MNCLCDA reported an average AUPR of 0.9224.
  • Case study validation: Case studies involving drugs like piperlongumine and sunitinib demonstrated MNCLCDA's ability to predict relevant circRNAs, with a significant portion of these predictions being validated against independent databases (CTRP). For piperlongumine, 15 out of 20 predicted circRNAs were confirmed.
  • Ablation study confirms module contributions: Experiments with model variants showed that each component (RWR, mixed-neighbourhood GCN, contrastive learning, and Laplacian regularization) contributes positively to the overall predictive performance.

Limitations and Future Work

  • Limited experimental data: The authors acknowledge that the number of experimentally validated circRNA-drug sensitivity associations is still relatively small, which can introduce bias and limit the reliability of predictions.
  • Future data collection: To improve prediction accuracy, the authors plan to collect more validated associations and incorporate other biological information, such as disease-drug and disease-circRNA associations.
  • Expanding data sources: Future work will focus on leveraging multiple sources of data to enhance the predictive capabilities of the model.
  • Further method development: The paper suggests that further efforts are needed in developing computational methods for predicting these associations, indicating ongoing research in this area.

Summary updated

Abstract

circRNAs play an important role in drug resistance and cancer development. Recently, many studies have shown that the expressions of circRNAs in human cells can affect the sensitivity of cells to therapeutic drugs, thus significantly influencing the therapeutic effects of these drugs. Traditional biomedical experiments required to verify this sensitivity relationship are not only time-consuming but also expensive. Hence, the development of an efficient computational approach that can accurately predict the novel associations between drug sensitivities and circRNAs is a crucial and pressing need. In this research, we present a novel computational framework called MNCLCDA, which aims to predict the potential associations between drug sensitivities and circRNAs to assist with medical research. First, MNCLCDA quantifies the similarity between the given drug and circRNA using drug structure information, circRNA gene sequence information, and GIP kernel information. Due to the existence of noise in similarity information, we employ a preprocessing approach based on random walk with restart for similarity networks to efficiently capture the useful features of circRNAs and drugs. Second, we use a mixed neighbourhood graph convolutional network to obtain the neighbourhood information of nodes. Then, a graph-based contrastive learning method is used to enhance the robustness of the model, and finally, a double Laplace-regularized least-squares method is used to predict potential circRNA-drug associations through the kernel matrices in the circRNA and drug spaces. Numerous experimental results show that MNCLCDA outperforms six other advanced methods. In addition, the excellent performance of our proposed model in case studies illustrates that MNCLCDA also has the ability to predict the associations between drug sensitivity and circRNA in practical situations. After a large number of experiments, it is illustrated that MNCLCDA is an efficient tool for predicting the potential associations between drug sensitivities and circRNAs, thereby can provide some guidance for clinical trials.
BibTeX
@inproceedings{li2023mnclcda,
  author = {Guanghui Li and Feifan Zeng and Jiawei Luo and Cheng Liang and Qiu Xiao},
  title = {{MNCLCDA: predicting circRNA-drug sensitivity associations by using mixed neighbourhood information and contrastive learning}},
  booktitle = {BMC Medical Informatics Decis. Mak},
  year = {2023},
  url = {https://openreview.net/forum?id=EGT77qxDr3},
}
Figure